Intralymphatic histiocytosis in a patient with lung adenocarcinoma treated with pembrolizumab: a case report

BACKGROUND: Pembrolizumab, an anti-programmed cell death-1 protein monoclonal antibody, is effective for patients with advanced non-small-cell lung cancer. However, immune checkpoint inhibitors such as pembrolizumab induce various immune-related adverse events, involving the lung, liver, gastrointes...

Descripción completa

Detalles Bibliográficos
Autores principales: Sugano, Teppei, Seike, Masahiro, Funasaka, Yoko, Yoshida, Mai, Takayama, Ryoko, Okamura, Ken, Nakanishi, Asuka, Tanaka, Toru, Takeuchi, Susumu, Noro, Rintaro, Minegishi, Yuji, Kubota, Kaoru, Saeki, Hidehisa, Gemma, Akihiko
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391791/
https://www.ncbi.nlm.nih.gov/pubmed/30813943
http://dx.doi.org/10.1186/s40425-019-0534-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391791/
https://www.ncbi.nlm.nih.gov/pubmed/30813943
http://dx.doi.org/10.1186/s40425-019-0534-z

Ejemplares similares